Company intelligence / Profile preview

EnteroBiotix

Glasgow, Scotland, United Kingdomenterobiotix.com ↗

Ownership: Private
Employees: ~53
Development stage: Phase 2

Overview

EnteroBiotix has reported promising safety and efficacy data from a completed Phase Ib study in liver cirrhosis, showing improvements in gut barrier function and patient-reported outcomes. Interim analysis from a Phase II IBS-C cohort has generated positive efficacy signals. Ongoing partnered trials include a Phase IIa study with Imperial College London targeting Allo-HSCT patients.

Therapeutic areas: GastroenterologyHematology
Modalities: Full-spectrum microbial therapeutics (microbiome-based therapies)
Industry: Biotech

Drug pipeline

3 assets

EBX-102

2 more assets in the full pipeline.

Request access →

Partnerships

Imperial College London – partnered clinical trial(s) in Allo-HSCT patients.Functional Gut Clinic – partnership for IBS clinical trial.

Beyond the preview

Go deeper on EnteroBiotix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EnteroBiotix.

Explore the full profile